Bostjan Seruga1, Aleksander Sadikov, Eduardo L Cazap, Lucia Beatriz Delgado, Raghunadharao Digumarti, Natasha B Leighl, Mohamed M Meshref, Hironobu Minami, Eliezer Robinson, Nise Hitomi Yamaguchi, Doug Pyle, Tanja Cufer. 1. Institute of Oncology Ljubljana, Ljubljana, Slovenia; Faculty of Computer and Information Science, University of Ljubljana, Ljubljana, Slovenia; Latin American-Caribbean Society of Medical Oncology, Buenos Aires, Argentina; Hospital de Clínicas, University of Uruguay, Montevideo, Uruguay; Nizam's Institute of Medical Sciences, Hyderabad, India; Princess Margaret Cancer Center, Toronto, Ontario, Canada; Faculty of Medicine, Cairo University, Cairo, Egypt; Division of Medical Oncology/Hematology, Kobe University Hospital, Kobe, Japan; Faculty of Medicine, Technion, Haifa, Israel; Institute of Advances in Medicine and University of São Paulo, São Paulo, Brazil; American Society of Clinical Oncology, Alexandria, Virginia, USA; University Clinic Golnik, Golnik, Slovenia.
Abstract
BACKGROUND: There are concerns about growing barriers to cancer research. We explored the characteristics of and barriers to global clinical cancer research. METHODS: The American Society of Clinical Oncology International Affairs Committee invited 300 selected oncologists with research experience from 25 countries to complete a Web-based survey. Fisher's exact test was used to compare answers between participants from high-income countries (HICs) and low- and middle-income countries (LMICs). Barriers to clinical cancer research were ranked from 1 (most important) to 8 (least important). Mann-Whitney's nonparametric test was used to compare the ranks describing the importance of investigated obstacles. RESULTS: Eighty oncologists responded, 41 from HICs and 39 from LMICs. Most responders were medical oncologists (62%) at academic hospitals (90%). Researchers from HICs were more involved with academic and industry-driven research than were researchers from LMICs. Significantly higher proportions of those who considered their ability to conduct academic research and industry-driven research over the past 5 years more difficult were from HICs (73% vs. 27% and 70% vs. 30%, respectively). Concerning academic clinical cancer research, a lack of funding was ranked the most important (score: 3.16) barrier, without significant differences observed between HICs and LMICs. Lack of time or competing priorities and procedures from competent authorities were the second most important barriers to conducting academic clinical research in HICs and LMICs, respectively. CONCLUSION: Lack of funding, lack of time and competing priorities, and procedures from competent authorities might be the main global barriers to academic clinical cancer research.
BACKGROUND: There are concerns about growing barriers to cancer research. We explored the characteristics of and barriers to global clinical cancer research. METHODS: The American Society of Clinical Oncology International Affairs Committee invited 300 selected oncologists with research experience from 25 countries to complete a Web-based survey. Fisher's exact test was used to compare answers between participants from high-income countries (HICs) and low- and middle-income countries (LMICs). Barriers to clinical cancer research were ranked from 1 (most important) to 8 (least important). Mann-Whitney's nonparametric test was used to compare the ranks describing the importance of investigated obstacles. RESULTS: Eighty oncologists responded, 41 from HICs and 39 from LMICs. Most responders were medical oncologists (62%) at academic hospitals (90%). Researchers from HICs were more involved with academic and industry-driven research than were researchers from LMICs. Significantly higher proportions of those who considered their ability to conduct academic research and industry-driven research over the past 5 years more difficult were from HICs (73% vs. 27% and 70% vs. 30%, respectively). Concerning academic clinical cancer research, a lack of funding was ranked the most important (score: 3.16) barrier, without significant differences observed between HICs and LMICs. Lack of time or competing priorities and procedures from competent authorities were the second most important barriers to conducting academic clinical research in HICs and LMICs, respectively. CONCLUSION: Lack of funding, lack of time and competing priorities, and procedures from competent authorities might be the main global barriers to academic clinical cancer research.
Authors: Catherine De Angelis; Jeffrey M Drazen; Frank A Frizelle; Charlotte Haug; John Hoey; Richard Horton; Sheldon Kotzin; Christine Laine; Ana Marusic; A John P M Overbeke; Torben V Schroeder; Hal C Sox; Martin B Van Der Weyden Journal: N Engl J Med Date: 2004-09-08 Impact factor: 91.245
Authors: Martine Piccart; Aron Goldhirsch; William Wood; Kathleen Pritchard; José Baselga; Linda Reaby; Ingrid Kössler; Stella Kyriakides; Larry Norton; Alan Coates Journal: Nature Date: 2007-03-08 Impact factor: 49.962
Authors: Carol P Somkin; Andrea Altschuler; Lynn Ackerson; Ann M Geiger; Sarah M Greene; Judy Mouchawar; Joan Holup; Louis Fehrenbacher; Andrew Nelson; Andrew Glass; Jonathan Polikoff; Sigrid Tishler; Carolyn Schmidt; Terry Field; Edward Wagner Journal: Am J Manag Care Date: 2005-07 Impact factor: 2.229
Authors: P N Lara; R Higdon; N Lim; K Kwan; M Tanaka; D H Lau; T Wun; J Welborn; F J Meyers; S Christensen; R O'Donnell; C Richman; S A Scudder; J Tuscano; D R Gandara; K S Lam Journal: J Clin Oncol Date: 2001-03-15 Impact factor: 44.544
Authors: Fidel Rubagumya; Sarah K Nyagabona; Khadija H Msami; Achille Manirakiza; Ahuka N Longombe; Theoneste Maniragaba; Hilary Chan; Alan Paciorek; Li Zhang; Emmanuel Balandya; Leyna H Germana; Elia J Mmbaga; Nazima Dharsee; Katherine Van Loon Journal: Oncologist Date: 2019-03-22
Authors: Priya Ranganathan; Girish Chinnaswamy; Manju Sengar; Durga Gadgil; Shivakumar Thiagarajan; Balram Bhargava; Christopher M Booth; Marc Buyse; Sanjiv Chopra; Chris Frampton; Satish Gopal; Nick Grant; Mark Krailo; Ruth Langley; Prashant Mathur; Xavier Paoletti; Mahesh Parmar; Arnie Purushotham; Douglas Pyle; Preetha Rajaraman; Martin R Stockler; Richard Sullivan; Soumya Swaminathan; Ian Tannock; Edward Trimble; Rajendra A Badwe; C S Pramesh Journal: Lancet Oncol Date: 2021-06-30 Impact factor: 54.433
Authors: Janani Vigneswaran; Yi-Hung Carol Tan; Septimiu D Murgu; Brian M Won; Kathryn Alexa Patton; Victoria M Villaflor; Philip C Hoffman; Thomas Hensing; D Kyle Hogarth; Renuka Malik; Heber MacMahon; Jeffrey Mueller; Cassie A Simon; Wickii T Vigneswaran; Christopher H Wigfield; Mark K Ferguson; Aliya N Husain; Everett E Vokes; Ravi Salgia Journal: Oncotarget Date: 2016-04-05
Authors: Anastassia Negrouk; Denis Lacombe; Fatima Cardoso; Franck Morin; Eva Carrasco; Joan Maurel; Rudolf Maibach; Enrique Aranda; Richard Marais; Rolf A Stahel Journal: ESMO Open Date: 2017-08-03